Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5794706 | 1.00 | TRPV1 (0.47) | TRPV1HSD11B1MAPTTRPA1KCNH2 | |
| SCHEMBL5454097 | 0.92 | TRPV1 (0.56) | TRPV1HSD11B1TRPA1KCNH2TRPM8 | |
| SCHEMBL5796835 | 0.92 | TRPV1 (0.56) | TRPV1HSD11B1TRPA1KCNH2TRPM8 | |
| SCHEMBL5462303 | 0.91 | TRPV1 (0.55) | TRPV1HSD11B1 | |
| SCHEMBL5793929 | 0.91 | TRPV1 (0.55) | TRPV1HSD11B1 | |
| SCHEMBL5444362 | 0.85 | TRPV1 (0.56) | TRPV1 | |
| SCHEMBL5792792 | 0.85 | TRPV1 (0.56) | TRPV1 | |
| SCHEMBL5451397 | 0.84 | TRPV1 (0.49) | TRPV1 | |
| SCHEMBL5794420 | 0.84 | TRPV1 (0.49) | TRPV1 | |
| SCHEMBL5794107 | 0.80 | TRPV1 (0.45) | TRPV1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | claimed |
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | GPR35, NPY1R, BDKRB1 | TRPV1 402/4885HSD11B1 2136/4885MAPT 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.